D-Lysine
Based on 1 Customer Validation
D-Lysine is the D-enantiomer of L-Lysine (HY-N0469). D-Lysine is metabolically inert and not utilized for protein synthesis by mammalian ribosomes. D-Lysine blocks renal uptake of 111In/90Y-Octreotide (HY-P0036)-based probes without inhibiting uptake by tumor/receptor tissues, and thus acts as a renoprotective agent in diagnostic imaging and peptide receptor radionuclide therapy (PRRT). D-Lysine specifically inhibits the early steps of non-enzymatic glycation by competing with glucose via its free amino group, theoretically, it can serve as a glycation competitor that "does not interfere with protein synthesis" under chronic hyperglycemia in diabetes. D-Lysine can be used in research related to cancer and diabetes.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 99.91%
- CAS. Nr.: 923-27-3
- Formel: C6H14N2O2
- Molecular Weight:146.19
-
Speicherung:
-20°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Biologische Aktivität
|
Human Endogenous Metabolite |
D-Lysine (0.25-4.0 mM; 10-20 days) significantly inhibits the non-enzymatic binding of glucose to human albumin, IgG, collagen, and isolated human glomerular basement membrane in vitro. Its inhibitory effect is directly correlated with the concentration of D-Lysine and is enhanced with increasing glucose concentrations (statistically significant under 10 and 20 mM glucose conditions)[2].
D-Lysine (0.25-2.0 mM; 10 days) reduces the formation of ketamines in human albumin (50 g/L) co-incubated with 10 mM glucose in a dose-dependent manner in vitro, and a linear correlation exists between the concentration of D-Lysine and the reduction in fructosamine levels[2].
D-Lysine (0.25-2.0 mM; 10 days) inhibits non-enzymatic binding of glucose to human albumin at physiological concentration (50 g/L) in vitro. In undiluted samples, inhibitory effects are detectable at 0.25 mM, while in diluted samples, detection requires a concentration of 0.5 mM[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
D-Lysine (400 mg/kg; i.v.; single co-injection) reduces renal uptake of 90Y-DOTATOC (HY-106033) by 65% without altering radiopharmaceutical distribution in blood or somatostatin receptor-positive organs[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Wistar rats (male, 200-250 g)[1]
-
Dosage:400 mg/kg (i.v. co-injection); 800 mg/kg (i.v. co-injection); 400 mg/kg (p.o. 15 min prior); 400 mg/kg (p.o. 30 min prior)
-
Administration:i.v.; single co-injection; p.o.; single injection 15 minutes prior; p.o.; single injection 30 minutes prior
-
Result:Reduced renal uptake of 111In-DTPA-Octreotide by more than 50% at 1, 4, and 24 hours post-injection (400 mg/kg i.v.).
Reduced renal uptake of 111In-DTPA-Octreotide by more than 50% at 1, 4, and 24 hours post-injection (800 mg/kg i.v.).
Reduced renal uptake of 111In-DTPA-Octreotide by 20% (400 mg/kg p.o., 15 minutes prior).
Reduced renal uptake of 111In-DTPA-Octreotide by 30% (400 mg/kg p.o., 30 minutes prior).
Had no significant effect on 111In-DTPA-Octreotide clearance from blood or uptake in somatostatin receptor-positive organs (pancreas, adrenal glands).
-
Animal Model:Wistar rats (male, 200-250 g)[1]
-
Dosage:400 mg/kg
-
Administration:i.v.; single co-injection
-
Result:Reduced renal uptake of 90Y-DOTATOC to 34.8% of control values, representing a 65% reduction.
Left radioactivity levels in blood, pancreas, and adrenal glands unaffected.
Chemical Information
-
CAS. Nr. 923-27-3
-
Appearance Solid
-
Molecular Weight 146.19
-
Formel C6H14N2O2
-
Color White to off-white
-
Structure Classification
-
Initial Source
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
-20°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Lösungsmittel & Löslichkeit
H2O : 100 mg/mL (684.04 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Reinheit & Dokumentation
-
Data Sheet (271 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Bernard BF, et al. D-lysine reduction of indium-111 octreotide and yttrium-90 octreotide renal uptake. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 1997 Dec;38(12):1929-33. [Content Brief]
[2]. Sensi M, et al. D-lysine effectively decreases the non-enzymic glycation of proteins in vitro. Clinical chemistry. 1989 Mar;35(3):384-7. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O | 1 mM | 6.8404 mL | 34.2021 mL | 68.4041 mL | 171.0103 mL |
| 5 mM | 1.3681 mL | 6.8404 mL | 13.6808 mL | 34.2021 mL | |
| 10 mM | 0.6840 mL | 3.4202 mL | 6.8404 mL | 17.1010 mL | |
| 15 mM | 0.4560 mL | 2.2801 mL | 4.5603 mL | 11.4007 mL | |
| 20 mM | 0.3420 mL | 1.7101 mL | 3.4202 mL | 8.5505 mL | |
| 25 mM | 0.2736 mL | 1.3681 mL | 2.7362 mL | 6.8404 mL | |
| 30 mM | 0.2280 mL | 1.1401 mL | 2.2801 mL | 5.7003 mL | |
| 40 mM | 0.1710 mL | 0.8551 mL | 1.7101 mL | 4.2753 mL | |
| 50 mM | 0.1368 mL | 0.6840 mL | 1.3681 mL | 3.4202 mL | |
| 60 mM | 0.1140 mL | 0.5700 mL | 1.1401 mL | 2.8502 mL | |
| 80 mM | 0.0855 mL | 0.4275 mL | 0.8551 mL | 2.1376 mL | |
| 100 mM | 0.0684 mL | 0.3420 mL | 0.6840 mL | 1.7101 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
D-Lysine Related Classifications
HY-Y1091 Related Classifications
Powered by Bioz